×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
NRSN – neurosense therapeutics ltd. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
NRSN
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/25
11:17 am
nrsn
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
3/24
09:00 am
nrsn
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
Neutral
Report
NeuroSense Advances Toward Key Regulatory Milestones with Strengthened Data Package and Near-Term Alzheimer's Readout
3/18
08:12 am
nrsn
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference [Yahoo! Finance]
Medium
Report
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference [Yahoo! Finance]
3/18
08:00 am
nrsn
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
Medium
Report
PrimeC New Data to Be Presented at AD/PD™ 2026 Conference
3/17
09:03 am
nrsn
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
Low
Report
NeuroSense Therapeutics (NRSN) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.
3/16
12:04 pm
nrsn
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity [Yahoo! Finance]
Medium
Report
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity [Yahoo! Finance]
3/16
11:33 am
nrsn
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
Medium
Report
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
3/10
08:03 am
nrsn
NeuroSense Therapeutics (NRSN) is now covered by Roth Mkm. They set a "buy" rating and a $3.00 price target on the stock.
Medium
Report
NeuroSense Therapeutics (NRSN) is now covered by Roth Mkm. They set a "buy" rating and a $3.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/24
10:11 am
nrsn
Form 6-K NeuroSense Therapeutics For: Mar 24
Low
Report
Form 6-K NeuroSense Therapeutics For: Mar 24
3/18
03:56 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Pellizzari Christine A
Medium
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Pellizzari Christine A
3/18
03:36 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Claiborne Cary J
Low
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Claiborne Cary J
3/18
03:36 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Tracik Ferenc
Low
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Tracik Ferenc
3/18
03:36 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Leuchtenberger Mark
Low
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Leuchtenberger Mark
3/18
03:36 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Golan Roy
Low
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Golan Roy
3/18
03:35 pm
nrsn
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Binder Hagit
Low
Report
Form 3 NeuroSense Therapeutics For: Mar 18 Filed by: Binder Hagit
3/16
12:28 pm
nrsn
Form 6-K NeuroSense Therapeutics For: Mar 16
Low
Report
Form 6-K NeuroSense Therapeutics For: Mar 16
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: